Jazz Pharmaceuticals' dispute with Avadel produced a Federal Circuit Hatch-Waxman decision on what kind of regulatory act can support an infringement suit.
The court rejected a broad theory that a regulatory filing by itself creates artificial infringement. It emphasized the statutory role of ANDA certification and notice in triggering the special Hatch-Waxman cause of action.
The case matters for Orange Book and drug-launch strategy because regulatory positioning can create commercial leverage, but the patent statute still defines when a court case exists.
For life-sciences teams, the decision should sit beside patent-listing and delisting disputes: the regulatory and patent lanes interact, but they are not interchangeable.